Premium
Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy
Author(s) -
Hashmi Hamza,
Bachmeier Christina,
Chavez Julio C.,
Song Jinming,
Hussaini Mohammad,
Krivenko Gabriel,
Nishihori Taiga,
Kotani Hiroshi,
Davila Marco L.,
Locke Frederick L.,
Jain Michael D.
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16155
Subject(s) - medicine , cytokine release syndrome , macrophage activation syndrome , immunology , hemophagocytic lymphohistiocytosis , chimeric antigen receptor , hemophagocytosis , tocilizumab , rituximab , diffuse large b cell lymphoma , lymphoma , t cell , pancytopenia , bone marrow , disease , immune system , rheumatoid arthritis , arthritis
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom